Table 1.
Demographic and baseline characteristics of AZA‐treated patients
| Characteristics | N (%) |
|---|---|
| Age | |
| Median (range) | 77 (56‐89) |
| >75 years | 55 (59%) |
| ≤75 years | 38 (41%) |
| Gender (male) | 55 (59%) |
| PS ECOG | |
| 0‐1 | 61 (66%) |
| 2‐3 | 26 (28%) |
| Missing | 6 (6%) |
| Albumin (g/L) | |
| ≤35 | 34 (37%) |
| >35 | 47 (50%) |
| Missing | 12 (13%) |
| LDH level (UI/L) | |
| ≤250 | 40 (43%) |
| >250 | 42 (45%) |
| Missing | 11 (12%) |
| Ferritin level (ng/mL) | |
| ≥1000 | 19 (21%) |
| <1000 | 44 (47%) |
| Missing | 30 (32%) |
| Blasts | |
| Median (range) | 13% (4‐30) |
| Cytopenias | |
| 0‐1 | 32 (34%) |
| 2‐3 | 61 (66%) |
| WHO diagnosis | |
| CRMD | 2 (2%) |
| AREB1 | 10 (11%) |
| AREB2 | 44 (47%) |
| LMMC2 | 15 (16%) |
| AML | 22 (24%) |
| Transfusion dependence | |
| Yes | 45 (48%) |
| Cytogenetic risk (IPSS) | |
| Favorable | 46 (49%) |
| Intermediate | 14 (15%) |
| Poor | 27 (29%) |
| Missing | 6 (7%) |
| Cytogenetic risk (IPSS‐R) | |
| Very good | 6 (6%) |
| Good | 46 (50%) |
| Intermediate | 10 (11%) |
| Poor | 5 (5%) |
| Very poor | 20 (22%) |
| Missing | 6 (6%) |
| IPSS risk score | |
| Intermediate risk 2 (1.5‐2) | 57 (61.3%) |
| High risk (2.5‐3) | 31 (33.3%) |
| Missing | 5 (5.4%) |
| IPSS‐R risk score | |
| Intermediate > 3‐4.5 | 22 (24%) |
| High > 4.5‐6 | 35 (38%) |
| Very high > 6 | 30 (32%) |
| Missing | 6 (6%) |
AML, acute myeloid leukemia; AZA, Azacitidine.